Immuneering (IMRX) Gains from Investment Securities (2020 - 2024)
Historic Gains from Investment Securities for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to -$5469.0.
- Immuneering's Gains from Investment Securities fell 12267.92% to -$5469.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$6784.0, marking a year-over-year decrease of 7222.65%. This contributed to the annual value of -$6784.0 for FY2024, which is 7222.65% down from last year.
- Latest data reveals that Immuneering reported Gains from Investment Securities of -$5469.0 as of Q4 2024, which was down 12267.92% from -$1315.0 recorded in Q3 2024.
- Over the past 5 years, Immuneering's Gains from Investment Securities peaked at $3.8 million during Q2 2022, and registered a low of -$5469.0 during Q4 2024.
- Its 5-year average for Gains from Investment Securities is $1.5 million, with a median of $336626.0 in 2020.
- Per our database at Business Quant, Immuneering's Gains from Investment Securities skyrocketed by 83383.04% in 2021 and then crashed by 12267.92% in 2024.
- Quarter analysis of 5 years shows Immuneering's Gains from Investment Securities stood at $1.8 million in 2020, then soared by 58.75% to $2.9 million in 2021, then plummeted by 100.18% to -$5170.0 in 2022, then skyrocketed by 52.5% to -$2456.0 in 2023, then plummeted by 122.68% to -$5469.0 in 2024.
- Its Gains from Investment Securities was -$5469.0 in Q4 2024, compared to -$1315.0 in Q3 2024 and -$2456.0 in Q4 2023.